MHRA launches women’s health evidence programme for UK medicines and devices

MHRA launches women’s health evidence programme for UK medicines and devices
Closing women’s health gaps

A new MHRA programme is being rolled out to close long-standing evidence gaps in how medicines and medical devices affect women across the UK. The initiative is part of the regulator’s broader 2030 strategy on health inequalities and comes as official data shows very low representation of pregnant and breastfeeding women in clinical trials.

Highlights

  • MHRA launches Women's Health Programme to address evidence gaps in pregnancy, reproductive health, and conditions specific to women, as only 1.1% of trials included pregnant women and 0.6% included breastfeeding women from 2019–2023.
  • The UK FemTech sector generates nearly £300 million in annual turnover, with MHRA aiming to accelerate innovation and patient access by encouraging earlier engagement from researchers and industry.
  • Recent regulatory changes, such as low-dose Estradiol vaginal product reclassification, have expanded treatment access for thousands, with MHRA's new programme targeting similar improvements in evidence and medicine availability.

Programme scope and evidence gaps

As reported by GOV.UK, the Medicines and Healthcare products Regulatory Agency is launching its Women’s Health Programme to improve evidence on how the risks and benefits of medicines and medical devices may differ for women and to support innovation in the sector.

The regulator says women remain underrepresented in research despite accounting for 51% of the population. It highlights persistent gaps in evidence covering pregnancy, reproductive health and conditions that are specific to women, as well as illnesses that present differently or disproportionately in women.

An MHRA analysis of 4,616 UK clinical trial applications submitted between 2019 and 2023 shows pregnant women are represented in only 1.1% of trials, while breastfeeding women appear in 0.6%. The agency says the programme will bring together patients, researchers, healthcare professionals and industry to strengthen the evidence base while maintaining standards on safety, quality and effectiveness.

Women’s Health Minister Baroness Gillian Merron says the programme, alongside the renewed Women’s Health Strategy, is intended to deliver better evidence, better treatments and a health system that responds more effectively to women. MHRA Chief Executive Lawrence Tallon says stronger evidence can help identify important differences in outcomes, support researchers and innovators and improve the tailoring of healthcare to women’s needs.

Innovation push and sector impact

The programme also has a commercial and regulatory development angle for the UK life sciences sector. The MHRA says women’s health is a major area for innovation, with the UK FemTech sector already generating annual turnover of nearly £300 million across reproductive health, long-term conditions and healthy ageing.

By engaging researchers and innovators earlier, the regulator says it wants to create conditions for promising products to be developed and reach patients sooner. The Health Research Authority says its joint guidance with the MHRA on Inclusion and Diversity Plans gives researchers a practical framework to make study populations more representative from the design stage.

Industry group PAGB says better evidence can widen access to appropriate treatments, including through medicine reclassification that supports self-care. It points to the reclassification of low-dose Estradiol vaginal products and Estriol cream as examples of regulatory change improving access to hormone replacement therapy for thousands of women.

The programme has been shaped with patient input through the MHRA’s Patient and Public Community and a Patients Association focus group. The announcement is being made at the inaugural DIA-MHRA Global Summit in London on 16-17 November 2026 during London Life Sciences Week.

We have previously noted the planned UK-EU SPS deal aimed at cutting post-Brexit border checks and paperwork for plant and food trade.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.